YF Vax 17D Strain

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Yellow FeverYellow Fever ImmunisationZika Virus Infection

Phase 1

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

CompletedNCT02743455

National Institute of Allergy and Infectious Diseases (NIAID)Yellow Fever, Yellow Fever Immunisation

Start: 2016-07-05End: 2018-03-22Updated: 2026-02-09

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

CompletedNCT02963909

National Institute of Allergy and Infectious Diseases (NIAID)Zika Virus Infection

Start: 2016-11-01End: 2018-10-30Updated: 2024-04-22

Related Papers

Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.

2023-06-2715 citations

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.

2017-12-05230 citations

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.

2017-12-05156 citations